NASDAQ$CRVS
Corvus Pharmaceuticals Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Provided business update and reported financial results for the fourth quarter and year ended December 31, 2021
Corvus Pharmaceuticals reported a net loss of $9.2 million for the fourth quarter of 2021, with research and development expenses totaling $4.8 million. As of December 31, 2021, the company's cash, cash equivalents, and marketable securities amounted to $69.5 million.
- Advanced three clinical programs for product candidates targeting CD73, the adenosine 2A receptor, and ITK.
- Initiated mid-stage clinical trials in front-line treatment of lung cancer and renal cell cancer.
- Partnership with Angel Pharmaceuticals has expanded clinical development of CPI-818 for T cell lymphomas into China.
- Company had cash, cash equivalents and marketable securities totaling $69.5 million as of December 31, 2021.
Headline financials
Revenue & EPS history
Corvus Pharmaceuticals · Revenue · Quarterly
$100M
Forward guidance
Corvus expects full year 2022 net cash used in operating activities to be between $34 million and $36 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
+1.0%
Avg return
Earnings day
+3.6%
Avg return
5 days after
+7.3%
Avg return
30 days after
53%
20 / 38 earnings
Positive
+32.2%
Q1 2025
Best reaction
-18.4%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +6.6% | +8.6% | — | |
| Q3 2025 | -1.4% | +3.5% | +15.3% | |
| Q2 2025 | +4.4% | +21.1% | +49.2% | |
| Q1 2025 | +32.2% | +8.1% | +16.7% | |
| Q4 2024 | -14.8% | -19.1% | -7.6% | |
| Q3 2024 | -7.2% | -14.3% | -15.5% | |
| Q1 2024 | -12.5% | +8.3% | +15.6% | |
| Q4 2023 | -2.6% | -5.8% | -25.8% | |
| Q3 2023 | +8.1% | -6.1% | +13.5% | |
| Q2 2023 | +10.5% | +7.2% | -21.5% | |
| Q1 2023 | +8.3% | +70.8% | +190.4% | |
| Q4 2022 | +11.1% | +40.0% | +75.4% | |
| Q3 2022 | -3.4% | -8.3% | +18.1% | |
| Q2 2022 | -5.0% | +12.4% | +11.4% | |
| Q1 2022 | -7.3% | -10.9% | -22.6% | |
| Q4 2021 | -8.5% | -11.5% | +4.8% | |
| Q3 2021 | +9.5% | +10.4% | -27.8% | |
| Q2 2021 | +0.5% | +1.9% | +11.5% | |
| Q1 2021 | -2.1% | -1.4% | -4.9% | |
| Q4 2020 | +7.3% | +2.8% | -1.7% | |
| Q3 2020 | +4.2% | +7.4% | +6.1% | |
| Q2 2020 | +1.9% | -1.7% | -12.7% | |
| Q1 2020 | -15.0% | +19.8% | +36.4% | |
| Q4 2019 | -18.4% | -27.5% | -47.9% | |
| Q3 2019 | -4.6% | -5.5% | -17.2% | |
| Q2 2019 | -3.1% | -9.0% | -12.8% | |
| Q1 2019 | +7.7% | +6.4% | -15.8% | |
| Q4 2018 | +0.0% | -6.0% | -8.5% | |
| Q3 2018 | +8.7% | -0.3% | -21.2% | |
| Q2 2018 | -6.8% | -7.0% | +12.8% | |
| Q1 2018 | -0.3% | +0.1% | +36.0% | |
| Q3 2017 | +4.2% | -1.8% | -18.6% | |
| Q2 2017 | +3.5% | -1.6% | +36.6% | |
| Q1 2017 | +3.2% | +2.0% | +16.9% | |
| Q4 2016 | +18.1% | +25.5% | -41.1% | |
| Q3 2016 | +3.7% | +8.7% | +17.1% | |
| Q2 2016 | +4.1% | +7.4% | +4.1% | |
| Q1 2016 | -5.4% | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro